Abstract
Purpose
Paget’s disease (PD) of the breast as well as the vulva is a rare condition that accounts for about 4% of breast neoplasms and 1% of vulvar malignancies. Recurrent disease after breast and vulvar surgery might be a challenge. To evaluate relevant molecules therapeutically, tissue from mammary and vulvar PD lesions was investigated immunohistochemically.
Methods
Histopathologic samples from 11 patients with mammary PD and eight patients with vulvar PD were stained with antibodies against estrogen and progesterone receptors, HER-2/neu and COX-2 followed by semiquantitative evaluation of the staining results.
Results
All tested mammary lesions as well as seven out of eight vulvar PD were negative for estrogen and progesterone receptors. Strong membranous staining for HER-2/neu (Score 3) was seen in all cases. Six out of 8 vulvar and 10 out of 11 mammary PD showed COX-2 overexpression.
Conclusions
PD of the breast and vulva are negative for estrogens and progesterons, therefore, anti-hormonal therapy is not indicated. The high frequency of Her-2/neu and COX-2 overexpression, however, suggests that these molecules could be therapeutically relevant in patients with PD. These results require further investigation.
Similar content being viewed by others
References
Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90:423–429
Brummer O, Stegner HE, Bohmer G, Kuhnle H, Petry KU (2004) HER-2/neu expression in Paget disease of the vulva and the female breast. Gynecol Oncol 95:336–340
Crawford D, Nimmo M, Clement PB, Thomson T, Benedet JL, Miller D, Gilks CB (1999) Prognostic factors in Paget’s disease of the vulva: a study of 21 cases. Int J Gynecol Pathol 18:351–359
Davies G, Martin LA, Sacks N, Dowsett M (2002) Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 13:669–678
De Potter CR, Schelfhout AM (1995) The neu-protein and breast cancer. Virchows Arch 426:107–115
Evans JF, Kargman SL (2004) Cancer and cyclooxygenase-2 (COX-2) inhibition. Curr Pharm Des 10:627–634
Fanning J, Lambert HC, Hale TM, Morris PC, Schuerch C (1999) Paget’s disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget’s disease, and recurrence after surgical excision. Am J Obstet Gynecol 180:24–27
Ferrandina G, Ranelletti FO, Salutari V, Gessi M, Legge F, Zannoni GF, Scambia G, Lauriola L (2004) Expression of cyclooxygenase-2 (COX-2) in non-neoplastic and neoplastic vulvar epithelial lesions. Gynecol Oncol 92:537–544
Fishman DA, Chambers SK, Schwartz PE, Kohorn EI, Chambers JT (1995) Extramammary Paget’s disease of the vulva. Gynecol Oncol 56:266–270
Fox H, Wells M (2003) Recent advances in the pathology of the vulva. Histopathology 42:209–216
Fu W, Lobocki CA, Silberberg BK, Chelladurai M, Young SC (2001) Molecular markers in Paget disease of the breast. J Surg Oncol 77:171–178
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ; Panel members (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583
Half E, Ming Tang X, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62:1676–1681
Harris RE, Namboodiri KK, Farrar WB (1996) Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7:203–205
Kawase K, Dimaio DJ, Tucker SL, Buchholz TA, Ross MI, Feig BW, Kuerer HM, Meric-Bernstam F, Babiera G, Ames FC, Singletary SE, Hunt KK (2005) Paget’s disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol 12:391–397
Liegl B, Horn LC, Moinfar F (2005) Androgen receptors are frequently expressed in mammary and extramammary Paget’s disease. Mod Pathol 18:1283–1288
Olson DJ, Fujimura M, Swanson P, Okagaki T (1991) Immunohistochemical features of Paget’s disease of the vulva with and without adenocarcinoma. Int J Gynecol Pathol 10:285–295
Reich O, Liegl B, Tamussino K, Regauer S (2005) p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget’s disease. Mod Pathol 18:354–357
Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637–2645
Tebes S, Cardosi R, Hoffman M (2002) Paget’s disease of the vulva. Am J Obstet Gynecol 187:281–283
van Diest PJ, van Dam P, Henzen-Logmans SC (1997) A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. Clin Pathol 50: 801–804
Witton CJ, Hawe SJ, Cooke TG, Bartlett JM (2004) Cyclooxygenase-2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 45:47–54
Zollo JD, Zeitouni NC (2000) The Roswell Park Cancer Institute experience with extramammary Paget’s disease. Br J Dermatol 142:59–65
Acknowledgments
The authors thank Mrs. Regina Scherling T.A. and Kathleen Fahr T.A. for their technical help in performing immunohistochemistry and Mrs. Alexandra Meinel, M.Sc. for her help in collecting the survival data. The authors also thank Cornelia Leo, M.D. for proofreading the manuscript and for her helpful discussion during the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Horn, LC., Purz, S., Krumpe, C. et al. COX-2 and Her-2/neu are overexpressed in Paget’s disease of the vulva and the breast: results of a preliminary study. Arch Gynecol Obstet 277, 135–138 (2008). https://doi.org/10.1007/s00404-007-0434-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-007-0434-1